Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc. (FHTX) is a clinical-stage biopharmaceutical pioneer developing precision medicines targeting chromatin regulation in oncology. This news hub provides investors and industry professionals with essential updates on the company's therapeutic pipeline, strategic collaborations, and clinical milestones.
Access timely reports on FHTX's innovative programs including FHD-286 (hematologic cancers), FHD-609 (synovial sarcoma), and FHD-909 (non-small cell lung cancer). Stay informed about regulatory developments, partnership announcements, and scientific presentations related to their Gene Traffic Control platform.
Our curated news collection serves as a comprehensive resource for tracking progress across preclinical studies, clinical trials, and business operations. Bookmark this centralized source for verified updates on Foghorn's novel protein degraders and chromatin-targeting therapies.
Flagship Pioneering, a bioplatform innovation company, has expanded its leadership team with new appointments and promotions. These changes accompany an expanded capital base of $3.6 billion for the development of 25 breakthrough platform companies in human health, sustainability, and AI.
Key promotions include Lovisa Afzelius to General Partner, Paul Biondi to General Partner, Dina Ciarimboli as General Counsel, Marcello Damiani as Senior Partner, Gary Pisano as Chief Strategist, and other critical roles filled by experienced professionals. These leaders bring significant expertise from major firms like Pfizer, Bristol-Myers Squibb, Moderna, and Harvard Business School.
Flagship aims to leverage these appointments to drive innovation, enhance strategic partnerships, and improve operational efficiency across its ecosystem of companies, furthering its mission to pioneer transformative technologies.
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company focused on treating serious diseases by correcting abnormal gene expression, announced its participation in two major investor conferences in June 2024. The Jefferies Global Healthcare Conference will feature Adrian Gottschalk, CEO, presenting on June 5, 2024, at 3:30 p.m. ET in New York. The Goldman Sachs 45th Annual Global Healthcare Conference will also include a presentation by Gottschalk on June 10, 2024, at 3:20 p.m. ET in Miami Beach. Both presentations will be accessible via webcast for 30 days on the company's website.
Foghorn Therapeutics has successfully closed a registered direct offering, raising approximately $110 million. This funding will bolster the company’s platform and advance its diverse pipeline of treatments for diseases, especially in oncology. The offering, which includes new and existing investors like BVF Partners and Flagship Pioneering, strengthens Foghorn's balance sheet, extending its cash runway into 2027. With $310 million in cash, cash equivalents, and short-term investments, the company is well-positioned for upcoming data readouts and clinical milestones. The offering priced 12,743,039 common shares at $5.51 each, and pre-funded warrants to buy 7,220,794 shares at $5.5099 each.
Foghorn Therapeutics (FHTX) has announced a registered direct offering of 12,743,039 shares of its common stock at $5.51 per share and pre-funded warrants for 7,220,794 shares at $5.5099 per warrant. This offering aims to raise approximately $110 million in gross proceeds. The closing is expected around May 22, 2024, pending customary conditions. Proceeds will be used for advancing preclinical and clinical programs and general corporate purposes. Jefferies, TD Cowen, and Evercore ISI are managing the offering. The securities are offered pursuant to an effective shelf registration statement filed with the SEC.
Foghorn Therapeutics Inc. provided a financial and corporate update for Q1 2024. The company showcased strong preclinical anti-tumor activity in multiple pipeline programs and progress in AML and NSCLC studies, with data expected in the second half of 2024. IND filing for a first-in-class oral BRM inhibitor was submitted, along with updates on selective CBP and EP300 degrader programs. The company presented promising data at AACR, appointed a new CFO, and reported cash reserves of $206.7 million.
